Systemic Radiotherapy with Monoclonal Antibodies: Options and Problems
Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor an...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1996
|
| Schriftenreihe: | Recent Results in Cancer Research
141 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology |
| Beschreibung: | 1 Online-Ressource (IX, 198 p) |
| ISBN: | 9783642799525 |
| DOI: | 10.1007/978-3-642-79952-5 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046145166 | ||
| 003 | DE-604 | ||
| 005 | 20211122 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1996 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642799525 |9 978-3-642-79952-5 | ||
| 024 | 7 | |a 10.1007/978-3-642-79952-5 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-79952-5 | ||
| 035 | |a (OCoLC)1119090189 | ||
| 035 | |a (DE-599)BVBBV046145166 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XH 3303 |0 (DE-625)152889:13132 |2 rvk | ||
| 084 | |a YR 3000 |0 (DE-625)154100:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Systemic Radiotherapy with Monoclonal Antibodies |b Options and Problems |c edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1996 | |
| 300 | |a 1 Online-Ressource (IX, 198 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Recent Results in Cancer Research |v 141 | |
| 520 | |a Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 0 | 7 | |a Radionuklid |0 (DE-588)4133541-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Strahlentherapie |0 (DE-588)4057833-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Radionuklid |0 (DE-588)4133541-7 |D s |
| 689 | 0 | 2 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |D s |
| 689 | 0 | 3 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Strahlentherapie |0 (DE-588)4057833-1 |D s |
| 689 | 1 | 2 | |a Monoklonaler Antikörper |0 (DE-588)4040094-3 |D s |
| 689 | 1 | 3 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Sautter-Bihl, Marie-Luise |d 1951- |0 (DE-588)1100095985 |4 edt | |
| 700 | 1 | |a Bihl, Heiner |d 1944- |0 (DE-588)1112627677 |4 edt | |
| 700 | 1 | |a Wannenmacher, Michael |d 1938-2015 |0 (DE-588)115523588 |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642799549 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540602095 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642799532 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-79952-5 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525351 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-79952-5 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180481509425152 |
|---|---|
| any_adam_object | |
| author2 | Sautter-Bihl, Marie-Luise 1951- Bihl, Heiner 1944- Wannenmacher, Michael 1938-2015 |
| author2_role | edt edt edt |
| author2_variant | m l s b mlsb h b hb m w mw |
| author_GND | (DE-588)1100095985 (DE-588)1112627677 (DE-588)115523588 |
| author_facet | Sautter-Bihl, Marie-Luise 1951- Bihl, Heiner 1944- Wannenmacher, Michael 1938-2015 |
| building | Verbundindex |
| bvnumber | BV046145166 |
| classification_rvk | XH 3303 YR 3000 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-79952-5 (OCoLC)1119090189 (DE-599)BVBBV046145166 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-642-79952-5 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04192nmm a2200685zcb4500</leader><controlfield tag="001">BV046145166</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20211122 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1996 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642799525</subfield><subfield code="9">978-3-642-79952-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-79952-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-79952-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119090189</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145166</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3303</subfield><subfield code="0">(DE-625)152889:13132</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YR 3000</subfield><subfield code="0">(DE-625)154100:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Systemic Radiotherapy with Monoclonal Antibodies</subfield><subfield code="b">Options and Problems</subfield><subfield code="c">edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (IX, 198 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Recent Results in Cancer Research</subfield><subfield code="v">141</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Radionuklid</subfield><subfield code="0">(DE-588)4133541-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Strahlentherapie</subfield><subfield code="0">(DE-588)4057833-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Radionuklid</subfield><subfield code="0">(DE-588)4133541-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Strahlentherapie</subfield><subfield code="0">(DE-588)4057833-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Monoklonaler Antikörper</subfield><subfield code="0">(DE-588)4040094-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sautter-Bihl, Marie-Luise</subfield><subfield code="d">1951-</subfield><subfield code="0">(DE-588)1100095985</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bihl, Heiner</subfield><subfield code="d">1944-</subfield><subfield code="0">(DE-588)1112627677</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wannenmacher, Michael</subfield><subfield code="d">1938-2015</subfield><subfield code="0">(DE-588)115523588</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642799549</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540602095</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642799532</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-79952-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525351</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-79952-5</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046145166 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:27Z |
| institution | BVB |
| isbn | 9783642799525 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525351 |
| oclc_num | 1119090189 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (IX, 198 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | Recent Results in Cancer Research |
| spelling | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher Berlin, Heidelberg Springer Berlin Heidelberg 1996 1 Online-Ressource (IX, 198 p) txt rdacontent c rdamedia cr rdacarrier Recent Results in Cancer Research 141 Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology Oncology Radiotherapy Oncology Radionuklid (DE-588)4133541-7 gnd rswk-swf Monoklonaler Antikörper (DE-588)4040094-3 gnd rswk-swf Strahlentherapie (DE-588)4057833-1 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Radionuklid (DE-588)4133541-7 s Monoklonaler Antikörper (DE-588)4040094-3 s Immuntherapie (DE-588)4026640-0 s DE-604 Strahlentherapie (DE-588)4057833-1 s Sautter-Bihl, Marie-Luise 1951- (DE-588)1100095985 edt Bihl, Heiner 1944- (DE-588)1112627677 edt Wannenmacher, Michael 1938-2015 (DE-588)115523588 edt Erscheint auch als Druck-Ausgabe 9783642799549 Erscheint auch als Druck-Ausgabe 9783540602095 Erscheint auch als Druck-Ausgabe 9783642799532 https://doi.org/10.1007/978-3-642-79952-5 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems Oncology Radiotherapy Oncology Radionuklid (DE-588)4133541-7 gnd Monoklonaler Antikörper (DE-588)4040094-3 gnd Strahlentherapie (DE-588)4057833-1 gnd Immuntherapie (DE-588)4026640-0 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4133541-7 (DE-588)4040094-3 (DE-588)4057833-1 (DE-588)4026640-0 (DE-588)4073781-0 (DE-588)4143413-4 |
| title | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems |
| title_auth | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems |
| title_exact_search | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems |
| title_full | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher |
| title_fullStr | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher |
| title_full_unstemmed | Systemic Radiotherapy with Monoclonal Antibodies Options and Problems edited by Marie-Luise Sautter-Bihl, Heiner Bihl, Michael Wannenmacher |
| title_short | Systemic Radiotherapy with Monoclonal Antibodies |
| title_sort | systemic radiotherapy with monoclonal antibodies options and problems |
| title_sub | Options and Problems |
| topic | Oncology Radiotherapy Oncology Radionuklid (DE-588)4133541-7 gnd Monoklonaler Antikörper (DE-588)4040094-3 gnd Strahlentherapie (DE-588)4057833-1 gnd Immuntherapie (DE-588)4026640-0 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Oncology Radiotherapy Oncology Radionuklid Monoklonaler Antikörper Strahlentherapie Immuntherapie Krebs Medizin Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-642-79952-5 |
| work_keys_str_mv | AT sautterbihlmarieluise systemicradiotherapywithmonoclonalantibodiesoptionsandproblems AT bihlheiner systemicradiotherapywithmonoclonalantibodiesoptionsandproblems AT wannenmachermichael systemicradiotherapywithmonoclonalantibodiesoptionsandproblems |